UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000036528
Receipt number R000041611
Scientific Title Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB
Date of disclosure of the study information 2019/04/17
Last modified on 2020/10/18 21:30:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB

Acronym

Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB

Scientific Title

Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB

Scientific Title:Acronym

Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB

Region

Japan


Condition

Condition

Pancreatic mass

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the optimal visible core length required in the pathological diagnosis in EUS-FNB using a Franseen needle.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To evaluate the optimal whitish material length required in the pathological diagnosis in EUS-FNB using a Franseen needle.

Key secondary outcomes

Factor affecting correct diagnosis
The relationship between whitish material length and amount of sample.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1 Pancreatic lesions that was detected by imaging examination (e.g. CT, MRI, PET-CT, US, and EUS) and required pathological diagnosis.
2 Age >=20 y
3 Ability to understand and willingness to sign a written statement of informed consent

Key exclusion criteria

1 ECOG PS 4
2 Patients who receive anticoagulant agent.
3 Pregnant or possibly pregnant women.
4 Bleedinfg tendency
5 Patients who are judged inappropriate by medical examine.

Target sample size

90


Research contact person

Name of lead principal investigator

1st name Hirotoshi
Middle name
Last name Ishiwatari

Organization

Shizuoka Cancer Center

Division name

Division of Endoscopy

Zip code

411-8777

Address

1007, Shimonagakubo, Nagaizumicho, Suntougun, Shizuoka

TEL

0559895222

Email

h.ishiwatari@scchr.jp


Public contact

Name of contact person

1st name Hirotoshi
Middle name
Last name Ishiwatari

Organization

Shizuoka Cancer Center

Division name

Division of Endoscopy

Zip code

411-8777

Address

1007, Shimonagakubo, Nagaizumicho, Suntougun, Shizuoka

TEL

0559895222

Homepage URL


Email

h.ishiwatari@scchr.jp


Sponsor or person

Institute

Shizuoka Cancer Center

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shizuoka Cancer Center

Address

1007, Shimonagakubo, Nagaizumicho, Suntougun, Shizuoka

Tel

0559895222

Email

h.ishiwatari@scchr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

108

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 03 Month 19 Day

Date of IRB

2019 Year 03 Month 28 Day

Anticipated trial start date

2019 Year 04 Month 17 Day

Last follow-up date

2020 Year 05 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

To evaluate the optimal whitish material length required in the pathological diagnosis in EUS-FNB using a Franseen needle.


Management information

Registered date

2019 Year 04 Month 16 Day

Last modified on

2020 Year 10 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000041611


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name